Harvard Bioscience Reports Q2 2025 Revenue of $20.5M, Net Loss of $2.3M, and Credit Amendment

HARVARD BIOSCIENCE INC

2025-Q2 EPS reported -$1.19 vs consensus -$0.10 ▼ miss (-1066.7%)

Q2 2025 revenue of $20.5M vs $23.1M in Q2 2024; gross margin 56.4% vs 57.2%.
Net loss improved to ($2.3M) from ($2.9M); adjusted EBITDA rose to $1.5M from $1.3M.
Cash from operations was $2.8M, compared to ($0.8M) in Q2 2024.
Credit agreement amended waiving defaults; new refinance deadline set for December 5, 2025.
Q3 2025 revenue guidance $19M-$21M with gross margin 56%-58%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.